Back to Search
Start Over
E3508: Randomized trial of carboplatin (C), paclitaxel (P), bevacizumab (B) with or without cixutumumab (Cx) in patients (pts) with advanced non-squamous, non-small cell lung cancer (NSCLC)
- Source :
- Journal of Clinical Oncology. 34:9091-9091
- Publication Year :
- 2016
- Publisher :
- American Society of Clinical Oncology (ASCO), 2016.
-
Abstract
- 9091Background: Cx is a fully human IgG1 monoclonal antibody to the insulin-like growth factor type receptor 1 (IGF1R) that can potentially reverse resistance and enhance the efficacy of chemothera...
- Subjects :
- Oncology
Cancer Research
medicine.medical_specialty
Bevacizumab
business.industry
medicine.drug_class
food and beverages
non-small cell lung cancer (NSCLC)
Cixutumumab
medicine.disease
Monoclonal antibody
Carboplatin
law.invention
body regions
chemistry.chemical_compound
Randomized controlled trial
Paclitaxel
chemistry
law
Internal medicine
medicine
business
Insulin-like growth factor 1 receptor
medicine.drug
Subjects
Details
- ISSN :
- 15277755 and 0732183X
- Volume :
- 34
- Database :
- OpenAIRE
- Journal :
- Journal of Clinical Oncology
- Accession number :
- edsair.doi...........15268752b5274c89241fc8a5ac0060c3